CD93, an AML with MLL rearrangements marker expressed on leukemia stem cells (LSC), may also be a useful therapeutic target candidate for anti-LSC therapy and prognostic marker for quantitation of minimal residual disease25. This evidence concerns the gene KMT2A and acute myeloid leukemia.